325 related articles for article (PubMed ID: 31382960)
1. Using the Fatigue Severity Scale to inform healthcare decision-making in multiple sclerosis: mapping to three quality-adjusted life-year measures (EQ-5D-3L, SF-6D, MSIS-8D).
Goodwin E; Hawton A; Green C
Health Qual Life Outcomes; 2019 Aug; 17(1):136. PubMed ID: 31382960
[TBL] [Abstract][Full Text] [Related]
2. Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.
Hawton A; Green C; Telford C; Zajicek J; Wright D
Value Health; 2012 Dec; 15(8):1084-91. PubMed ID: 23244811
[TBL] [Abstract][Full Text] [Related]
3. The use of multiple sclerosis condition-specific measures to inform health policy decision-making: mapping from the MSWS-12 to the EQ-5D.
Hawton A; Green C; Telford CJ; Wright DE; Zajicek JP
Mult Scler; 2012 Jun; 18(6):853-61. PubMed ID: 22108867
[TBL] [Abstract][Full Text] [Related]
4. Health State Values Derived from People with Multiple Sclerosis for a Condition-Specific Preference-Based Measure: Multiple Sclerosis Impact Scale-Eight Dimensions-Patient Version (MSIS-8D-P).
Goodwin E; Green C; Hawton A
Value Health; 2018 Nov; 21(11):1338-1345. PubMed ID: 30442282
[TBL] [Abstract][Full Text] [Related]
5. Estimating a Preference-Based Index for an Eight-Dimensional Health State Classification System for Multiple Sclerosis.
Goodwin E; Green C; Spencer A
Value Health; 2015 Dec; 18(8):1025-36. PubMed ID: 26686787
[TBL] [Abstract][Full Text] [Related]
6. Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease.
Moore A; Young CA; Hughes DA
Value Health; 2018 Nov; 21(11):1322-1329. PubMed ID: 30442280
[TBL] [Abstract][Full Text] [Related]
7. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
[TBL] [Abstract][Full Text] [Related]
8. Health Utilities for Multiple Sclerosis.
Hawton A; Green C
Value Health; 2016 Jun; 19(4):460-8. PubMed ID: 27325338
[TBL] [Abstract][Full Text] [Related]
9. Mapping of the Gastrointestinal Short Form Questionnaire (GSF-Q) into EQ-5D-3L and SF-6D in patients with gastroesophageal reflux disease.
Monroy M; Ruiz MA; Rejas J; Soto J
Health Qual Life Outcomes; 2018 Sep; 16(1):177. PubMed ID: 30200982
[TBL] [Abstract][Full Text] [Related]
10. Psychometric performance of the CFQ-R-8D compared to the EQ-5D-3L and SF-6D in people with cystic fibrosis.
Mukuria C; Rowen D; Acaster S; McGarry LJ; Lou Y; Sosnay PR; Quittner AL
J Patient Rep Outcomes; 2024 Feb; 8(1):24. PubMed ID: 38416239
[TBL] [Abstract][Full Text] [Related]
11. Unchained melody: revisiting the estimation of SF-6D values.
Craig BM
Eur J Health Econ; 2016 Sep; 17(7):865-73. PubMed ID: 26359242
[TBL] [Abstract][Full Text] [Related]
12. Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis.
Versteegh M
Pharmacoeconomics; 2016 Nov; 34(11):1133-1144. PubMed ID: 27282692
[TBL] [Abstract][Full Text] [Related]
13. Estimating the disutility of relapse in relapsing-remitting and secondary progressive multiple sclerosis using the EQ-5D-5L, AQoL-8D, EQ-5D-5L-psychosocial, and SF-6D: implications for health economic evaluation models.
Ahmad H; Campbell JA; van der Mei I; Taylor BV; Xia Q; Zhao T; Palmer AJ
Qual Life Res; 2023 Dec; 32(12):3373-3387. PubMed ID: 37522942
[TBL] [Abstract][Full Text] [Related]
14. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey.
Longworth L; Yang Y; Young T; Mulhern B; Hernández Alava M; Mukuria C; Rowen D; Tosh J; Tsuchiya A; Evans P; Devianee Keetharuth A; Brazier J
Health Technol Assess; 2014 Feb; 18(9):1-224. PubMed ID: 24524660
[TBL] [Abstract][Full Text] [Related]
15. Comparing the Performance of 2 Health Utility Measures in the Medicare Health Outcome Survey (HOS).
Jia H; Lubetkin EI; DeMichele K; Stark DS; Zack MM; Thompson WW
Med Decis Making; 2018 Nov; 38(8):983-993. PubMed ID: 30403580
[TBL] [Abstract][Full Text] [Related]
16. Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D.
Teckle P; McTaggart-Cowan H; Van der Hoek K; Chia S; Melosky B; Gelmon K; Peacock S
Health Qual Life Outcomes; 2013 Dec; 11():203. PubMed ID: 24289488
[TBL] [Abstract][Full Text] [Related]
17. Testing alternative regression models to predict utilities: mapping the QLQ-C30 onto the EQ-5D-5L and the SF-6D.
Lamu AN; Olsen JA
Qual Life Res; 2018 Nov; 27(11):2823-2839. PubMed ID: 30173314
[TBL] [Abstract][Full Text] [Related]
18. A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia.
McCrone P; Patel A; Knapp M; Schene A; Koeter M; Amaddeo F; Ruggeri M; Giessler A; Puschner B; Thornicroft G
J Ment Health Policy Econ; 2009 Mar; 12(1):27-31. PubMed ID: 19346564
[TBL] [Abstract][Full Text] [Related]
19. Health Condition Impacts in a Nationally Representative Cross-Sectional Survey Vary Substantially by Preference-Based Health Index.
Hanmer J; Cherepanov D; Palta M; Kaplan RM; Feeny D; Fryback DG
Med Decis Making; 2016 Feb; 36(2):264-74. PubMed ID: 26314728
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.
Franken MD; de Hond A; Degeling K; Punt CJA; Koopman M; Uyl-de Groot CA; Versteegh MM; van Oijen MGH
Health Qual Life Outcomes; 2020 Jul; 18(1):240. PubMed ID: 32690011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
